Nanotechnology Now







Heifer International

Wikipedia Affiliate Button


DHgate

Home > Press > Convergen LifeSciences Announces Patent Award

Abstract:
Convergen LifeSciences, Inc. announced today that another United States Patent 7,977,468 has been awarded by the U.S. Patent and Trademark Office jointly to The University of Texas System Board of Regents and The Secretary, U.S. Department of Health and Human Services. The patent is one of 23 patents, pending or issued worldwide, licensed exclusively to Convergen LifeSciences, Inc. The patent covers CNVN202, a targeted molecular cancer therapy undergoing clinical evaluation in lung cancer patients.

Convergen LifeSciences Announces Patent Award

Austin, TX | Posted on July 14th, 2011

The '468 patent is based upon important discoveries made by a team of researchers from The University of Texas MD Anderson Cancer Center, The University of Texas Southwestern Medical Center and the National Cancer Institute. The discovery of the 3p21.3 family of tumor suppressor genes has been the subject of more than 20 peer-reviewed scientific publications demonstrating the genes' ability to control key anti-cancer mechanisms. CNVN202 harnesses TUSC2 (FUS1), the most potent inducer of apoptosis among the family of 3p21.3 cancer suppressor genes.

"The patent further solidifies our growing IP portfolio," stated Greg Heinlein, Chief Operating and Financial Officer, Convergen LifeSciences. "Broadly speaking, this patent expands the application of CNVN202 to virtually all cancers and extends the use of our patented technologies to include cancer diagnostic and screening tools."

Data from a phase I clinical study presented at the 2011 annual meeting of the American Association for Cancer Research showed for the first time that a tumor suppressor gene can be delivered intravenously and selectively to human cancer cells using a nanoparticle vector, express high levels of mRNA and protein in cancer cells in the primary tumor and distant metastatic sites, alter relevant pathways in the cancer cell and mediate clinically beneficial anti-cancer activity.

A phase II clinical trial is planned to evaluate CNVN202 in combination with TarcevaŽ (erlotinib) in lung cancer patients who would not be expected to benefit from erlotinib alone. CNVN202 has shown synergy when combined with erlotinib in both EGFR mutation positive and negative cancers.

TarcevaŽ is a registered trademark of the Roche Group including Genentech and Chugai and Astellas Pharma.

####

For more information, please click here

Contacts:
Greg Heinlein
Convergen LifeSciences, Inc.
(512) 372-4422

Copyright © PR Newswire Association LLC.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Keysight Technologies Shifts to Direct Sales of High-Performance Products in North America March 3rd, 2015

Cambrios and Heraeus Jointly Create New, High-Conductivity Transparent Conductors: Two Companies' Combined Products Dramatically Extend Flexible Substrate Capabilities for Next-Generation Mass-Market Technology Products March 3rd, 2015

The taming of magnetic vortices: Unified theory for skyrmion-materials March 3rd, 2015

Democratizing synthetic biology: New method makes research cheaper, faster, and more accessible March 3rd, 2015

Nanomedicine

Democratizing synthetic biology: New method makes research cheaper, faster, and more accessible March 3rd, 2015

Pens filled with high-tech inks for do-it-yourself sensors March 3rd, 2015

New nanodevice defeats drug resistance: Tiny particles embedded in gel can turn off drug-resistance genes, then release cancer drugs March 2nd, 2015

New Hopes for Treatment of Intestine Cancer by Edible Nanodrug March 2nd, 2015

Announcements

The taming of magnetic vortices: Unified theory for skyrmion-materials March 3rd, 2015

Democratizing synthetic biology: New method makes research cheaper, faster, and more accessible March 3rd, 2015

Pens filled with high-tech inks for do-it-yourself sensors March 3rd, 2015

Black phosphorus is new 'wonder material' for improving optical communication March 3rd, 2015

Patents/IP/Tech Transfer/Licensing

onic Present breakthrough in CMOS-based Transceivers for mm-Wave Radar Systems March 1st, 2015

New Paper-like Material Could Boost Electric Vehicle Batteries: Researchers create silicon nanofibers 100 times thinner than human hair for potential applications in batteries for electric cars and personal electronics February 20th, 2015

Nanotech Discoveries Move from Lab to Marketplace with Lintec Deal: Licensing Partnership Brings Together University Technology, New Richardson-Based Facility Directed by Alumni February 9th, 2015

Graphenea granted patent on graphene transfer February 9th, 2015

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More










ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2015 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE